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Abstract
The upsurge of immunocompromised patients has led to extensive study of fungal infections with
Candida albicans being the frontlinemodel of pathogenic yeast in humans. In the quest tofind novel
antifungal agents, this study reports the potential usage of wild-typeC. albicans strainC86 to
biosynthesise silver nanoparticles bymicrowave assisted technique. Visual colour change andUV-
spectrophotometer were used for primary detection of silver nanoparticles. Additionally, the FTIR
peaks confirm the particles’ formation and surface characterisation techniques such as FESEMand
EDX suggests that the silver nanoparticles were sized in the range of 30–70 nm. Furthermore,
pioneeringwork of homologous recombination techniquewas systematically employed to delete
uncharacterized gene orf19.3120 (CNP41) in the C86 strain creating the deletion strainC403 ofC.
albicans. To amalgamate the two significantfindings, biosynthesized silver nanoparticles were
subjected to antifungal studies by disk diffusion assay on the strainC403 that lacks the gene orf19.3120
(CNP41) ofC. albicans. As a synergetic approach, combinational effect was studied by incorporating
antifungal drugfluconazole. Both individual and enhanced combinational antifungal effects of silver
nanoparticles andfluconazole were observed on geneticallymodifiedC403 strainwith 40% increase
in fold area compared towild-type C86 strain. This can be attributed to the synergetic effect of the
bonding reaction betweenfluconazole andAgNPs. Taken together, thisfirst-ever interdisciplinary
study strongly suggests that theCNP41 gene could play a vital role in drug resistance in this fungal
pathogen.
1. Introduction
Diverse populations ofmicrobes like bacteria and fungi have advertently inhabited the human racewith the
passage of time. Although some of themicrobial interactions have been beneficial, yet their detrimental effects
are numerous. Of late, with increase in the number of immunocompromised patients, the study of fungal
infections has gainedmore prominence inmedical researchwithCandida albicans being one of the frontline
model of pathogenic yeast in humans [1].C. albicans is a diploid fungus, polymorphic in nature having the
ability to grow as yeast, pseudohyphae and true hyphae [2, 3]. Several studies demonstrated thatC. albicans is the
most prevalent fungal pathogen that can causemultiple diseases ranging from superficial infections ofmucous
membranes to life-threatening systemic candidemia [1, 4].
In the last few decades, several antifungal drugs have been developed to treatCandida infections. Based on
their chemical composition andmode of action, antifungals have been classified into different groups such as
allylamines, azoles, echinocandins, 5-fluorocytosine and polyenes [5]. Among these groups, azole class of
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therapy or repeated use of these antifungals leads to the development of resistance among the candida species
which could in turn affect the individuals havingweak defencemechanisms [6]. To overcome the current
challenges witnessed in the existing conventional antifungal agents, the present work addresses the dire need to
explore a novel antifungal agent whichwould also be cost-effective with lesser side effects.
Several alternative strategies to produce antifungal agents include antifungal peptides, efflux pump
inhibitors, essential oils, nanoparticles, oxidative stressmarkers, phytochemicals and statins tomention a few
[7]. Among these,metal oxide nanoparticles have several advantages which include intracellular free radical
generation, large surface to volume ratio,membrane damage,metal ion release andmultiple cellular targets that
can prevent the risk of resistance development [8]. Recent studies suggest that the importance of silver in the
health care sector has driven research to shift from ionic or colloidal silver based usage to silver nanoparticles
(AgNPs) as they have a better safety profile.Moreover, AgNPs have a broad spectrumof antibacterial, antifungal
and antiviral activities [9, 10]. Nevertheless, the production of silver nanoparticles using physicochemical
methodswould be expensive, dangerous and toxic to human health and environment [11]. Therefore,
biosynthesis of silver nanoparticles to combat the environmental hazards sets the premise of the current study.
In recent years, literature emphasises the biosynthesis approach for producing silver nanoparticles due to its
simple, non-toxic, eco-friendly and cost-effective benefits.Moreover, it does not require any capping agents or
Figure 1. Flow diagram summarising the experimental studies performed in this work.
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surfactants whichwas required by physicochemicalmethods [12]. Themode of action of AgNPs using
biosynthesis approach is yet to be explored in detail and sporadic distribution of literature is seen regarding the
studies of antifungal properties of silver nanoparticles [10–13]. In the current study, novel work has been carried
out to synthesise AgNPs from awild-typeCandida strain C86 using biosynthesis approach andmicrowave
assisted technique. The formation of AgNPswas characterized by primary and secondary detection techniques.
Primary detection of presence of silver nanoparticles included the observation of the colour change of the
solution frompale yellow to brown, followed by FTIR analysis. Secondary detectionwas carried out by using a
double beamUVSpectrophotometer and further confirmed by EDX and FESEManalysis.
FromCandidaGenomeDatabase (CGD), it has been found that open reading frame (ORF)/gene orf19.3120
located on chromosome 4 on the right arm (chromosomal coordinates 1538056-1539795;ORF size 1740 bp)
remains uncharacterized and it has been predicted to be a putative PDR-subfamily ABC transporter using
bioinformatics approach [14]. ThisORF/gene has been taken in this study as it lacks any experimental evidence
to prove its role inC. albicans drug resistance arsenals.Moreover, it encodes a protein of half size of ABC
transporters Cdr1p andCdr2p. Therefore, we have attempted to investigate its role in drug resistance by novel
approach using AgNPs.Otherwise its function could have beenmasked by other stronger ABC transporters
encoded by the genesCDR1 andCDR2 andwould not be amenable for functional analysis. The nanoparticles
obtainedwere tested on the uncharacterized gene, orf19.3120 (designated asCNP41 gene). Both the copies of the
CNP41 genewere deleted in thewild-type strain C86 generating the strainC403 (cnp41Δ/cnp41Δ). Antifungal
activity of silver nanoparticles was tested onC403 strain using disk diffusionmethod.Nanoparticles alone and in
combinationwithfluconazole were used in this study.
2.Materials andmethods
2.1. Experimental procedure
Theflowchart of the procedures has been presented infigure 1. Briefly, double copy deletion ofCNP41 has been
done in twophases, Phase I and Phase II. Biosynthesis of silver nanoparticles was followed by its primary and
secondary detection and characterization. Lastly, these nanoparticles were tested onCNP41 deleted strain for
their antifungal activity.
2.2. Strains
Candida albicans strain C86 (Δura3::imm434/Δura3::imm434Δleu2::FRT/Δleu2::FRT)was derived from
CAF4-2 (Δura3::imm434/Δura3::imm434) [15] by deleting both the copies of LEU2 gene using construct
pKA76 [16] and evictingURA3flipper as described byMorschhäuser et al [17]. The plasmid pKA76was digested
withKpnI-SacI to release the deletion cassette and transformed into parental strainCAF4-2 to delete both the
copies of LEU2 gene andURA3flipper was evicted by incubating in yeast carbon base (YCB)media in presence
of bovine serum albumin as described byMorschhäuser et al [17]. The resulting strain C86was used for deleting
the geneCNP41 (orf19.3120). For routine amplification of plasmids and subcloning ofDNA fragments,
Escherichia coli strain XL-1 Bluewas used [18]. Table 1 details the strains used in this study.
2.3.Media and growth condition
Yeast extract/peptone/dextrose (YPD) and synthetic dextrose (SD)mediawere prepared for culturing the yeast
strain as described [19]. Uridine 50 μg ml−1 was supplemented additionally as per the requirement. Strains were
maintained in 15%v/v glycerol stock and stored in−80 °C.Candida albicans strains were streaked freshly to
avoid spontaneous chromosomal instability when required [20]. Bacterial strains were grown in yeast extract/
tryptone/sodium chloride (YT)media (0.5% sodium chloride, 0.5% yeast extract and 1% tryptone) at 37 °C.
Plasmidswere amplified in YTmedia containing 100 μg ml−1 of ampicillin.
2.4.Molecular biologymethods
PCR amplificationwas performed using a thermal cycler as described [21]. Restriction digestion of plasmids, gel
elution ofDNA fragments, ligation ofDNA fragments into vectors were carried out as described [22]. Plasmids
Table 1. List of strains.
Strains Description Phenotype Source
CAF4-2 Wild-type strain Ura- [15]
C86 Δura3::imm434/Δura3::imm434Δleu2::FRT/Δleu2::FRT Ura- Leu- This study
C386 Single copy deletant ofCNP41 gene Ura+ This study
C403 Double copies deletant ofCNP41 gene Leu+Ura+ This study
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were isolated by alkaline lysismethod [23].E. coli transformationwas carried out by calcium chloridemethod
[24].C. albicans transformationwas done by spheroplastmethod [25, 26].
2.5. Vectors, plasmid constructs and primers
Plasmid pUC19was used for cloning and sequencing purposes [27]. The plasmid pSFU1 containingURA3
flipper was provided by.Morschhäuser as a gift. The plasmid pKA16wasmade by subcloning a 1.4 kb SalI-PstI
fragment containingURA3 (digested out frompSFU1) into pUC19 at SalI/PstI site. The plasmid pKA16was
used as basic plasmid tomake constructs for gene/ORFdeletion. Primers used in this study are listed in table 2.
Primers KC16, KC17 (URA3) andKC195, KC206 (LEU2) aremade using internal sequences of selection
markers [16].
The LEU2 deletion construct wasmade by subcloning flanking sequences of LEU2 gene intoURA3flipper
plasmid pSFUI. Upstream and downstream sequences were amplified using the primers KC74/KC75 and
KC76/KC77 fromCAF4-2 genomicDNA. The PCRproducts were inserted into plasmid pSFUI atKpnI/XhoI
and SacI/NotI sites generating pKA76. The plasmid pKA76 can be digestedwithKpnI-SacI to release the deletion
cassette and transform into recipientCandida strain.
TheCNP41 gene deletionwas done as shown infigure 2. TheCNP41 gene deletion construct wasmade by
subcloning flanking sequences on either side of the selectionmarker. Briefly, two sets of primers, KC186/KC187
andKC188/KC189 (table 2)weremade by using theCandida albicans genome sequence available atCandida
GenomeDatabase. PCRproducts of 525 bp and 505 bpwere amplified using genomicDNAof parental
strainCAF4-2. These PCRproducts were cloned into pTZ57R/T vector using InsTAPCRCloning kit as
recommended by themanufacturer (ThermoFisher Scientific, Lithuania). Subsequently, these two products
were digested out frompTZ57R/T and inserted at SacI/BamHI andPstI/HindIII sites of pKA16 generating the
plasmid pKA244 carryingURA3marker forfirst copy deletion ofCNP41 gene. Second deletion construct
carrying the LEU2marker wasmade by replacingURA3with LEU2 (taken out frompKA188) gene in pKA244
resulting in the plasmid pKA594. The plasmid pKA244was digestedwith SacI/HindIII to release the deletion
cassette and transformed intoCandida strainC86 for deleting thefirst copy of theCNP41 gene. Subsequently,
the second copywas deleted by transforming a single copy deleted strainwith the plasmid pKA594. Plasmids
used in this study are listed in table 3.
2.6. Confirmation strategy for gene deletion
Deletion of theCNP41 genewas confirmed by PCRwith two pairs of primers for checking 5′ and 3′ junctions.
Double deletions were verifiedwith internal primers and the primers used for this purpose are listed in table 2.
PCRproducts of 5′ and 3′ junctions were also digestedwith restriction enzymes to ensure that there are no non-
specific amplifications.
Figure 2. Schematic diagramof deletion ofCNP41 gene located on chromosome 4.MS1 andMS2 areflanking sequences ofCNP41
gene.MS1was PCR amplified using primers P1 andP2;MS2 amplified using P3 and P4.URA3 and LEU2 are selectionmarkers.
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2.7. Biosynthesis of silver nanoparticles
Nanoparticles were synthesized using biosynthesis approach andmicrowave assisted technique usingwild-type
C. albicans strain C86. Procedure for nanoparticles biosynthesis has been briefly described herein. TheCandida
strainC86 stored in−80 °Cultra-freezer was streaked onYPDplate supplementedwith uridine (50 μg ml−1)
and incubated at 30 °C for 12–16 h to get barely visible young colonies. The cells were then inoculated into a
100 ml YPD liquid supplementedwith uridine (50 μg ml−1). Cells were incubated at 30 °C in shaking incubator
at 110 rpm for 16–18 h. The cells were filtered usingWhatman grade 01 filter paper [28]. 100 ml silver nitrate
solutionwas prepared usingMilliQwaterwith its concentration (0.1 M). The resultant 50 ml of cell filtrate was
taken andmixedwith silver nitrate solution in 1:1 ratio [29]. Themixture was then heated at 600W for 5 min till
themixture reduces Ag+ to Ag0 by changing its colour frompale yellow to brown [29].
2.8. Characterization of silver nanoparticles
The solution of prepared nanoparticles was subjected to double beamUV spectrophotometer (Systronics 2202,
India) for primary confirmation of synthesis of AgNPs. The silver nanoparticles sample was tested alongwith
controlmicrobial suspension. As silver nanoparticles’ range of wavelength falls under 400–480 nm, the range
was set at 200–800 nm. Furthermore, the synthesised AgNPswere centrifuged to obtain pellets and then
characterized by FTIR (JASCOV600, Japan) for observing the functional groups. EDX and FESEM (Carl Zeiss
sigma,Germany) techniqueswere incorporated to view size and shape of silver nanoparticles.
Table 2. List of Primers used in the study.
Primer no. Sequence (5′→3′) Purpose
KC74 TCGGGTACCGTTAGTTTCTATTATGGCCGTCAA Amplification of 990 bp upstreamof LEU2, will be
used for deletion this LEU2 usingURA3flipperKC75 TCGCTCGAGGGATATTGGTTTTAAAAGAAAGGA
KC76 TCGGCGGCCGCCAGTAGTTAGCATTTAAATTTCAAATACT Amplification of 988 bp downstreamof LEU2, will be
used for deletion this LEU2 usingURA3flipperKC77 TCGGAGCTCAATACGTTTATACCACGTGGTGAC
KC186 GAGCTCGAAGGCATCAAAGAAGGATTTG Amplification of 525 bp upstreamof orf19.3120, will
be used for deletingCNP41 geneKC187 GGATCCGACTTATTTGCAATTATTGTTAAAATG
KC188 CTGCAGCTCGTACAGAAATGTACTCTTTACG Amplification of 505 bp downstreamof orf19.3120,
will be used for deletingCNP41 geneKC189 AAGCTTCCCTGCTGCTGATAATCCTTAT
KC16 GTCTTGATTAAGCATACATAAGGAC For verifying deletion of orf19.3120, usingURA3
markerKC17 TGAAGTTGTTAGCACTGGAACTG
KC195 GATGATTTAGCACTTTCAAGAGC For verifying deletion of orf19.3120, using LEU2
markerKC206 AGCGGTATCAGAACAGCAGA
KC192 CATGTGACTCAATGGTATAATGATG For verifying deletion of upstream of orf19.3120,
upstreamonChr4
KC193 CAAACATGATTGTAGAAGAAGATC For verifying deletion of upstream of orf19.3120,
downstreamonChr4
KC398 ATGGCTCTGTTAGTGCTGGAGAA Internal primers ofCNP41 gene to verify double copy
deletion.KC 399 TGTACGCAACTGACATAAACGAC





pKA16 URA3marker cloned in pUC19 This study
pKA188 LEU2marker cloned in pUC19 This study
pKA244 CNP41 gene deletion construct
containingURA3marker
This study
pKA594 CNP41 gene deletion construct
containing LEU2marker
This study
pKA76 LEU2 deletion construct [16]
5
Mater. Res. Express 7 (2020) 125401 DDhabalia et al
2.9. Antifungal susceptibility test
Disc diffusion test was performed to evaluate the antifungal activity as described [30]. Sterile 6 mmdisks were
purchased fromHimedia, India. 20 μl of silver nanoparticles was pipetted onto the sterile disk. Standard disks of
fluconazole (10 μg,Himedia)was used as positive control and combination offluconazole withAgNPswas
impregnated on the disks for this study. SD plates containingCandida cells and diskwere incubated at 30 °C for
24–48 h until a clear zone of inhibitionwas formed. The diameter of these zones wasmeasured. The protocol
was followed as described [30]. Each test was conducted in triplicates to ensure reproducibility.
2.10. Assessment of increase in fold area
The increase in fold area was assessed by calculating themean surface area of the zone of inhibition of antifungal
activity offluconazole alone and fluconazole alongwith AgNPs. The percentage fold increase in area of tested
antifungal activity was calculated from equation (1):
( )= -fold increase in area of tested antifungal activity B A
A
% 100 1*
where, A is the zone of inhibition of tested antifungal alone andB is the zone of inhibition of tested antifungal
alongwith synthesized silver nanoparticle [31].
3. Results and discussion
3.1.Deletion ofCNP41 gene inCandida albicans
TheCandida albicans strain C86was transformedwith the plasmid pKA244 by digestingwith SacI/HindIII and
ura+ transformants were obtained on plate lacking uridine (ura- plate). The ura+ transformants were re-
streaked on the ura- plate to remove any false transformants. Transformants were independently processed for
making genomicDNA for PCR verification ofCNP41 gene deletion. PCR verification of the junctions was done
as shown infigure 3. Both 5′ and 3′ junctions were verified by primers KC16/KC192 andKC17/KC193
respectively. The expected sizes of amplified products for 5′ and 3′ junction verificationwould be 811 bp and
901 bp, respectively. The obtained PCRproducts were exactlymatchingwith the expected sizes (seefigure 4(a).
Further confirmation comes from the digestion of these PCRproducts with diagnostic restriction enzymes
producing the fragments of expected size (data not shown). Approximately 15 ura+ transformants were
screened by this process and 3 right candidates were obtained forfirst copy deletion ofCNP41 gene. Henceforth,
we refer orf19.3120 asCNP41 (CandidaNanoparticle 41). The strain carrying the first copy deletionwas
designated as C386.
For the deletion of the second copy of theCNP41 gene, the strainC386was transformedwith the plasmid
pKA594 and leu+ transformants were obtained on the SDplate lacking leucine. The transformants were
processed for genomicDNApreparation and subsequently PCRwas done to screen the right candidates. The
primers KC195/KC192 andKC206/KC193were used for verifying 5′ and 3′ junctions. Expected size of the PCR
products are 811 bp and 901 bp, respectively. The sizes of the PCRproducts obtained arematchingwith the
expected sizes (see figure 4(b)). PCRproducts were further digestedwith diagnostic restriction enzymes to
ensure that they are not non-specific bands (data not shown). Approximately 40 leu+ transformants were
screened and 8 right candidates were obtained. Deletion ofCNP41 genewas further confirmed by designing a
pair of internal deletion primers KC398/KC399whichwould fail to amplify any product in the double copy
deleted strainwhereas parental strainwould produce a band of 1035 bp (see figure 5). Thus, theCNP41 genewas
successfully deleted, generating the strainC403 (cnp41Δ/cnp41Δ).
Figure 3. Schematic diagramof primer design for verifying theCNP41 gene deletion. Chr4, chromosome 4 ofC. albicans; LFS and
RFS, flanking sequences on the left side and right side of the gene used formaking deletion constructs. Primers P5 and P8 are designed
from chromosomalDNA sequence outside LFS andRFSwhereas P6 and P7 are designed from selectionmarker which is used for
deletion.
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3.2. Biosynthesis of silver nanoparticles
Biosynthesis of silver nanoparticles using C86 strain ofC. albicanswas done bymicrowave assisted technique.
The primary confirmation of the synthesised AgNPswas authenticated as the solution colour changed frompale
yellow to brownish (see figure 6). Although some studies hypothesised that silver ions requireNDPHdependent
nitrate reductase enzyme for the reduction toAgNPs [28, 32], the exactmechanism of formation of AgNPs
Figure 5.PCR verification ofCNP41 gene nullmutant. Lane 1, 1 kbDNADNA ladder; lane 2, control PCRwithCAF4-2 genomic
DNA (1035 bp); lane 3, nullmutant (C403), no PCRproduct amplified.
Figure 4.PCR confirmation of 5′ and 3′ junctions ofCNP41 gene deletion inC403. (a)Deletion usingURA3 selectionmarker: lane 1,
5′ landingwith primers KC186/16 (775 bp); lane 2, 5′ junctionwith primers KC192/16 (811 bp); lane 3, 1 kbDNALadder; lane 4, 3′
landingwith primers KC189/17 (755 bp); lane 5, 3′ junctionwith primers KC193/17 (901 bp). (b)Deletion using LEU2 selection
marker: lane 1, 5′ landingwithKC186/195 (775 bp); lane 2, 5′ junctionwith primers KC192/195 (811 bp); lane 3, 1 kbDNALadder;
lane 4, 3′ Landingwith primers KC189/206 (755 bp); lane 5, 3′ junctionwith primers KC193/206 (901 bp).
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remains unanswered.One of the possible explanations for this study involvingC. albicans is that the fungal cells
secreteNDPHdependent nitrate reductase enzyme in their extracellular environment [29, 33].
3.2.1. Double beamUV spectrophotometer
Opticalmeasurements for the primary detection of silver nanoparticles was done usingUV-Visible
spectrophotometer (Systronics 2202, India) and the range of wavelengthwas set between 200–800 nm.As
depicted infigure 7(a), themaximumabsorbance peak observed at wavelength 446 nmwaswithin theAgNPs
peak range [30]. This is in accordance with several studies that reported the highest absorbance peak between
400–480 nm [28, 29].
Figure 7.Characterization results of the biosynthesized AgNPs. (a)UV spectra of biosynthesized AgNPs. (b) FTIR spectra recorded
from solid sample of synthesized AgNPs. (c) FESEM image of synthesized AgNPs. (d)EDX analysis plot of AgNPs fromwild-type
Candida albicans strain.
Figure 6. Synthesis of silver nanoparticles. (a)Transparent AgNO3 solution (left) and pale yellow liquid culture (right) and (b) brown
in colour synthesised AgNPs solution.
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3.2.2. FTIR studies
For further characterisation of AgNPs, the solutionwas centrifuged to obtain pellets. As depicted infigure 7(b),
FTIR solid sample analysis highlights the 6 bands involved, namely, 553.59, 598.92, 659.68, 1637.64, 3331.21
and 3340.85 cm−1. This confirms the presence of AgNPs alongwithmicrobial enzymes. A similar studywas
carried out byUkkund et alwherein the FTIR plots of biosynthesised AgNPs had peaks in the range of
4000–400 cm−1 [29]. This led to the understanding of the interactions between silver ions and enzymes in
microbial solutions to stabilise the AgNPs. Figure 7(b) further highlights the presence ofmicrobial proteinswith
the twisted shape of amide bonds. The peaks at 3340.85 (N–Hstretch amide), 3331.21(stretching vibrations of
primary amines), 1637.64 (C–Oamides), 659.68 (C–Nstretch amines), 553.59 (Ag–O) and 598.92 (C–Cl
stretching) cm−1 verifying the presence of Ag nanoparticles. These peaks signify the involvement ofN–H
elongated vibrations, N–Hbending vibrations andC=Oelongating vibrations leading tomicrobial-silver
nanoparticles aggregates [34]. The presence of the nitrate reductase enzymes on the surface of AgNPswas
confirmedwith theC–NandC–O–C stretching vibration [29]. Thefindings ofGole et al support this workwith
similar FTIR peaks describing the presence of AgNPs accompanied by enzymes andmicrobial proteins [35].
3.2.3. FESEMand EDXanalysis
The topology and size of AgNPswere characterised by FESEMand as seen infigure 7(c), the AgNPs synthesised
by using C86 strain ofC. albicanswas spherical in shape and its size ranged from30–70 nmwhich is in
accordancewith the previous studies wherein 66 nm spherical shaped silver nanoparticles were reported [33].
Moreover, there results obtained are also comparable with those that incorporated other fungi like penicillium
spp. [28, 29, 36]. Furthermore, EDX results are depicted infigure 7(d) and they are in accordance with the results
observed for the AgNPs peaks exhibited in the FTIR studies. Lastly, EDX results confirm that 85.7%of AgNPs
are present in the given sample and the results of this work is comparable with several studies reported in the
literature [28–31, 34].
3.3. Antifungal activity of AgNPs
The antifungal activity of AgNPswas carried out by incorporating antifungal agentfluconazole as it shows
fungistatic activity againstmost of the candida strains and helps in curing fungal infections [37].Moreover,
fluconazole belongs to azole class of antifungals and ismore preferred due to its broad spectrum activity, high
efficacy and low toxicity [6]. The zone of inhibition of AgNPswas studied againstCandida strain C403 having
both the copies ofCNP41 gene deleted. Thewild-type strain C86 has been used as a control. As seen infigure 8,
Figure 8.Zone of inhibition studies for analysis antifungal activity. Flu, fluconazole antifungal agent.
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the C86 strain ofC. albicans showed no zone on addition of AgNPswhereas theC403 strain showed a 10 mm
zone around the 6 mmdisk containing AgNPs. This finding is comparable with theworks published on
antifungal action onAgNPs by using ciprofloxacin [38], erythromycin [28] andfluconazole [35, 36, 38].
It has been shown earlier thatmetal andmetal oxide nanoparticles have always stood apart for being an
effective entities as antifungal agents [28, 29, 31]. Particularly, silver nanoparticles of triangle shaped and 75 nm
sizedwere demonstrated effectively for presenting antifungal activity with Erythromycin against penicillium spp.
[28], whereas spherical shaped silver nanoparticles of size 30–45 nmalongwith Erythromycin exhibited three-
fold antifungal activity against FuzariumOxysporum [29]. Additionally, copper oxide nanoparticles of size 7 nm
alongwith fluconazole were proven as effective antifungal agents againstC. albicans [39]. These results are
comparable with the current antifungal studywherein spherical biosynthesized silver nanoparticles of size
30–70 nmwere tested positively againstCandida albicans.
An enhancedmicrobial activity was seen as a promising result of having fluconazole antifungal agent with
the synthesised AgNPs and supported by theworks published by Balaji et al andGajbhiye et al [36, 38]. Table 4
illustrates the increase in fold area activity. It was further observed that C403 strain had an increase in fold area by
10.3%when compared to thewild-type strain C86with its fold area being 7.4%. This increase in the fold area can
be attributed to the synergetic effect of the bonding reaction betweenfluconazole andAgNPs. Interestingly,
AgNPs did not have any effect onwild-type C86 strainwith its genes intact and the presence of AgNPswere
insufficient to kill the strain.However, AgNPs had shown antifungal property onC403 strain having both the
copies ofCNP41 gene deleted. Thus, this study strongly suggests that theCNP41 gene could play a vital role in
drug resistance inC. albicans.
4. Conclusion
The biosynthesis of silver nanoparticles (AgNPs)was carried out usingwild-typeCandida albicans strainC86 by
adopting a novel approach. The formation of AgNPswas confirmed by severalmethods such as FTIR,UV
spectrophotometer, EDX and FESEM. The results obtained from these analyses clearly indicated the formation
of AgNPs. For testing the antifungal activity of this nanoparticles, a novelCandida strainC403 (cnp41Δ/
cnp41Δ) has been generated by deleting both the copies of theCNP41 genemaking the strain nullmutant for
this gene. The antifungal effect of AgNPswas studied onC403 (cnp41Δ/cnp41Δ) individually and in
combinationwith antifungal drug fluconazole by the disk diffusionmethodwhereas wild-type strainC86 serves
as a control. An individual and enhanced combinational antifungal effect of AgNPs and fluconazole was
observed onC403 strainwith an increase in fold area of 10.3%.On the other hand, C86 strain remains
unaffected for antifungal activity byAgNPs and amarginal increase was observedwhen in combinationwith
fluconazole. This can be attributed to the synergetic effect of the bonding reaction between fluconazole and
AgNPs. Thus, this study strongly suggests thatCNP41 gene plays a critical role in drug resistance inC. albicans.
Lastly, this work opens a plethora of opportunities to study the efficacy of AgNPs in various pathogenic fungi.
Additionally, extensive experimental and clinical trials could be carried out to comprehend better use of AgNPs
as a potential antimicrobial agent.
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